MSCs-FL-TRAIL showed superiority over MSCs-sTRAIL in terms of inducing anti-tumor effects in lung cancer lines, malignant pleural mesothelioma lines, colon cancer lines, renal cancer lines, oral squamous cell carcinoma line, and breast adenocarcinoma line (in vitro). The gene discussed is TNFSF10; the disease is lung carcinoma.